Based on the Windtree Therapeutics Inc stock forecast from 0 analysts, the average analyst target price for Windtree Therapeutics Inc is not available over the next 12 months. Windtree Therapeutics Inc’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of Windtree Therapeutics Inc is Slightly Bearish, which is based on 2 positive signals and 4 negative signals. At the last closing, Windtree Therapeutics Inc’s stock price was USD 0.50. Windtree Therapeutics Inc’s stock price has changed by +5.87% over the past week, -43.86% over the past month and -97.06% over the last year.
No recent analyst target price found for Windtree Therapeutics Inc
No recent average analyst rating found for Windtree Therapeutics Inc
Company Overview Windtree Therapeutics Inc
Windtree Therapeutics, Inc., a biotechnology company, focuses on the development of therapeutics for the treatment of acute cardiovascular diseases. The company's lead product candidate is istaroxime, which is in Phase 2b clinical trial for the treatment of acute decompensated heart failure, as well as for the treatment of early cardiogenic shock. It also develops AEROSURF, an aerosolized KL4 surfactant that is in Phase 2b clinical trial to treat respiratory distress syndrome in premature infants; Surfaxin, a lyophilized KL4 surfactant, which is in Phase 2a clinical trial for the treatment of lung injury resulting from COVID-19; Rostafuroxin that is in Phase 2b clinical trial for the treatment of genetically associated hypertension; and oral and intravenous SERCA2a activator, which is in preclinical trial for the treatment of chronic and acute heart failure. In addition, it is developing aPKCi Inhibitor for the treatment of cutaneous malignancies and solid tumors that is in preclinical trials. Windtree Therapeutics, Inc. has a collaboration with Universita degli Studi di Milano-Bicocca for the discovery and development of new SERCA2a compounds for the treatment of chronic and acute human heart failure; a strategic alliance with Laboratorios del Dr. Esteve, S.A. for the development, marketing, and sale of a portfolio of potential KL4 surfactant products; license, development and commercialization agreement with Lee's Pharmaceutical (HK) Ltd. and Zhaoke Pharmaceutical (Hefei) Co. Ltd.; license agreement with Philip Morris USA, Inc. and Johnson & Johnson; and collaboration with Battelle Memorial Institute for development of its ADS for use in its phase III program. The company was formerly known as Discovery Laboratories, Inc. and changed its name to Windtree Therapeutics, Inc. in April 2016. The company was founded in 1992 and is headquartered in Warrington, Pennsylvania. Read Less
Windtree Therapeutics, Inc., a biotechnology company, focuses on the development of therapeutics for the treatment of acute cardiovascular diseases. The company's lead product candidate is istaroxime, which is in Phase 2b clinical trial for the treatment of acute decompensated he...Read More
Frequently Asked Questions About Windtree Therapeutics Inc (WINT) Stock
Stock Target Advisor's fundamental analysis for Windtree Therapeutics Inc's stock is Slightly Bearish.
Unfortunately we do not have enough data on WINT's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on WINT's stock to indicate what its average analyst target is.
WINT stock's Price/Earning ratio is 0.89.
Our analysis grades WINT stock's Price / Earning ratio at C-. This means that WINT stock's Price/Earning ratio is above 30% of the stocks in the Biotechnology sector in the NSD exchange.
Based on this WINT may be undervalued for its sector.
The last closing price of WINT's stock was USD 0.50.
The most recent market capitalization for WINT is USD 5.12M.
Unfortunately we do not have enough analyst data on WINT's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains Windtree Therapeutics Inc's stock.
As per our most recent records Windtree Therapeutics Inc has 0 Employees.
Windtree Therapeutics Inc's registered address is 2600 Kelly Road, Warrington, PA, United States, 18976-3622.
You can get more information about it from Windtree Therapeutics Inc's website at https://windtreetx.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
Superior Earnings Growth
This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.
What not to like
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Low market capitalization
This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Overpriced on free cash flow basis
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Frequently Asked Questions About Windtree Therapeutics Inc (WINT) Stock
Stock Target Advisor's fundamental analysis for Windtree Therapeutics Inc's stock is Slightly Bearish.
Unfortunately we do not have enough data on WINT's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on WINT's stock to indicate what its average analyst target is.
WINT stock's Price/Earning ratio is 0.89.
Our analysis grades WINT stock's Price / Earning ratio at C-. This means that WINT stock's Price/Earning ratio is above 30% of the stocks in the Biotechnology sector in the NSD exchange.
Based on this WINT may be undervalued for its sector.
The last closing price of WINT's stock was USD 0.50.
The most recent market capitalization for WINT is USD 5.12M.
Unfortunately we do not have enough analyst data on WINT's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains Windtree Therapeutics Inc's stock.
As per our most recent records Windtree Therapeutics Inc has 0 Employees.
Windtree Therapeutics Inc's registered address is 2600 Kelly Road, Warrington, PA, United States, 18976-3622.
You can get more information about it from Windtree Therapeutics Inc's website at https://windtreetx.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for WINT !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
